Amyotrophic Lateral Sclerosis (Lou Gehrig's) - Drug Pipeline Analysis and Market Forecasts to 2016

Report Summary

GlobalData’s report, “Amyotrophic lateral sclerosis (Lou Gehrigs) - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global amyotrophic lateral sclerosis market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global amyotrophic lateral sclerosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global amyotrophic lateral sclerosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• Annualized global ALS market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
• Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases by mechanism of action being developed, and emerging trends. Key classes of mechanism of action include SOD1 protein folding stabilizers, dopamine agonists, immunomodulators and antioxidants.
• Analysis of the current and future market competition in the global ALS market. Key market players covered are Mitsubishi Tanabe Pharma Corporation, Avanir Pharmaceuticals, Avicena Group and Eisai Pharmaceuticals.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with ALS.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global amyotrophic lateral sclerosis market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global amyotrophic lateral sclerosis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global amyotrophic lateral sclerosis market landscape? – Identify, understand and capitalize.

1 Table of contents 

1.1 List of Tables 

1.2 List of Figures 

2 Amyotrophic Lateral Sclerosis Therapeutics Market: Market Characterization 

2.1 Overview 

2.2 ALS Therapeutics Market Size 

2.3 ALS Therapeutics Market Forecast and CAGR 

2.4 Drivers and Barriers for the ALS Therapeutics Market 

2.4.1 Drivers for the ALS Therapeutics Market 

2.4.2 Barriers for the ALS Therapeutics Market 

2.5 Opportunity and Unmet Need 

2.6 Key Takeaway 

3 Amyotrophic Lateral Sclerosis Therapeutics Market: Competitive Assessment 

3.1 Overview 

3.2 Strategic Competitor Assessment 

3.3 Product Profile for the Major Marketed Products in the ALS Therapeutics Market 

3.3.1 Rilutek (Riluzole) 

3.4 Key Takeaway 

4 Amyotrophic Lateral Sclerosis Therapeutics Market: Pipeline Assessment 

4.1 Overview 

4.2 Strategic Pipeline Assessment 

4.2.1 Technology Trends Analytic Framework 

4.3 ALS Therapeutics – Promising Drugs under Clinical Development 

4.4 Molecule Profile for Promising Drugs under Clinical Development 

4.4.1 Zenvia 

4.4.2 Radicut 

4.4.3 KNS-760704 

4.4.4 ONO-2506/Cereact 

4.4.5 SB-509 

4.4.6 E0302 

4.4.7 ISIS-SOD1Rx 

4.5 ALS Therapeutics Market – Clinical Pipeline by Mechanism of Action 

4.6 ALS Therapeutics Pipeline – Pipeline by Clinical Phases of Development 

4.6.1 ALS Therapeutics – Phase III Clinical Pipeline 

4.6.2 ALS Therapeutics – Phase II Clinical Pipeline 

4.6.3 ALS Therapeutics – Phase I Clinical Pipeline 

4.6.4 ALS Therapeutics – Pre-clinical Pipeline 

4.6.5 ALS Therapeutics – Discovery Pipeline 

4.7 Key Takeaway 

5 Amyotrophic Lateral Sclerosis Therapeutics Market: Implications for Future Market Competition 

6 Amyotrophic Lateral Sclerosis Therapeutics Market: Future Players in the ALS Therapeutics Market 

6.1 Introduction 

6.2 Mitsubishi Tanabe Pharma Corporation 

6.2.1 Overview 

6.2.2 ALS Portfolio 

6.2.3 ALS Pipeline Portfolio 

6.3 Eisai Pharmaceuticals 

6.3.1 Overview 

6.3.2 ALS Portfolio 

6.3.3 ALS Pipeline Portfolio 

6.4 Avanir Pharmaceuticals 

6.4.1 Overview 

6.4.2 ALS Portfolio 

6.4.3 ALS Pipeline Portfolio 

6.5 Isis Pharmaceuticals 

6.5.1 Overview 

6.5.2 ALS Portfolio 

6.5.3 ALS Pipeline Portfolio 

6.6 Sangamo BioSciences 

6.6.1 Overview 

6.6.2 ALS Portfolio 

6.6.3 ALS Pipeline Portfolio 

7 Amyotrophic Lateral Sclerosis Therapeutics Market: Appendix 

7.1 Definitions 

7.2 Acronyms 

7.3 Research Methodology 

7.3.1 Coverage 

7.3.2 Secondary Research 

7.3.3 Forecasting 

7.3.4 Primary Research 

7.3.5 Expert Panel Validation 

7.4 Contact Us 

7.5 Disclaimer 

7.6 Sources 

1.1 List of Tables

Table 1: ALS Therapeutics, Global, Market Revenues ($m), 2001-2009 7
Table 2: ALS Therapeutics, Global, Market Forecasts ($m), 2009-2017 8
Table 3: Major Marketed Products Comparison in the ALS Therapeutics Market, 2010 12
Table 4: ALS Therapeutics – Most Promising Drugs Under Clinical Development, 2010 15
Table 5: ALS Therapeutics – Phase III Clinical Pipeline, 2010 20
Table 6: ALS Therapeutics – Phase II Clinical Pipeline,  2010 20
Table 7: ALS Therapeutics – Phase I Clinical Pipeline,  2010 21
Table 8: ALS Therapeutics – Pre-clinical Pipeline,  2010 21
Table 9: ALS Therapeutics – Discovery Pipeline, 2010 22
Table 10: Mitsubishi Tanabe Pharma Corporation – ALS Pipeline Products, 2010 25
Table 11: Eisai Pharmaceuticals – ALS Pipeline Products, 2010 25
Table 12: Isis Pharmaceuticals – ALS Pipeline Products, 2010 26
Table 13: Sangamo BioSciences – ALS Pipeline Products, 2010 28

1.2 List of Figures

Figure 1: ALS Therapeutics, Global, Market Revenues ($m), 2001-2009 7
Figure 2: ALS Therapeutics, Global, Market Forecasts ($m), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the ALS Therapeutics Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for ALS, 2010 11
Figure 5: Technology Trends Analytic Framework of the ALS Pipeline, 2010 14
Figure 6: Technology Trends Analytic Framework  of the ALS Therapeutics Pipeline – Description, 2010 15
Figure 7: ALS Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 19
Figure 8: ALS Therapeutics Pipeline by Phase of Clinical Development, 2010 19
Figure 9: Implications for Future Market Competition in the ALS Market, 2010 23
Figure 10: ALS Therapeutics Market – Clinical Pipeline by Company, 2010 24
Figure 11: GlobalData  Market Forecasting Model 33